Applied BioCode (6598) — Cash Flow-to-Debt Ratio
Applied BioCode (6598) has a Cash Flow-to-Debt Ratio of -0.06x as of September 2025, meaning its operating cash flow of NT$-19.88 Million could theoretically repay 0% of its total liabilities (NT$343.23 Million) in one year. Check 6598 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Applied BioCode Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Applied BioCode across 12 annual periods. Also explore Applied BioCode balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Applied BioCode (2013–2024)
Year-by-year debt coverage analysis for Applied BioCode. For market capitalisation and broader financial context, see how much is Applied BioCode worth.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.62x | NT$-207.74 Million | NT$336.07 Million | ▼ -0.1% |
| 2023 | -0.62x | NT$-205.09 Million | NT$332.22 Million | ▼ -267.7% |
| 2022 | 0.37x | NT$145.87 Million | NT$396.38 Million | ▲ +128.1% |
| 2021 | -1.31x | NT$-151.77 Million | NT$116.01 Million | ▼ -25.0% |
| 2020 | -1.05x | NT$-146.74 Million | NT$140.23 Million | ▲ +37.2% |
| 2019 | -1.67x | NT$-313.84 Million | NT$188.36 Million | ▲ +52.7% |
| 2018 | -3.52x | NT$-286.71 Million | NT$81.35 Million | ▲ +15.1% |
| 2017 | -4.15x | NT$-250.36 Million | NT$60.30 Million | ▲ +52.7% |
| 2016 | -8.77x | NT$-448.96 Million | NT$51.17 Million | ▼ -70.6% |
| 2015 | -5.14x | NT$-209.24 Million | NT$40.67 Million | ▼ -55.6% |
| 2014 | -3.31x | NT$-128.80 Million | NT$38.97 Million | ▲ +15.0% |
| 2013 | -3.89x | NT$-91.93 Million | NT$23.63 Million | — |